Leora Horn is an Oncology physician affiliated with Vanderbilt University. OpenAlex indexes 276 publications with 17,677 citations (h-index 49); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 Tvc
Nashville, TN 372320001
Telephone
615-322-3000Registry record last updated 1 May 2012.
Clinical trials
- Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Sponsor: ECOG-ACRIN Cancer Research Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
36.3%Opioid Agonist9.3%Oxycodone Hcl54%Morphine Sulfate Er24%Fentanyl13%Oxycontin10%Part D<11 patientsGabapentinoids6.7%Gabapentin73%Pregabalin28%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
19.7%Proton pump inhibitor6.2%Omeprazole67%Pantoprazole Sodium33%Part D<11 patientsSerotonin-3 Receptor Antagonist5.1%Ondansetron Hcl77%Ondansetron Odt23%Part D<11 patients+ 5 more classes in this area
Blood & clotting
8%Factor Xa inhibitor6.7%Eliquis73%Xarelto28%Part D<11 patientsLow Molecular Weight Heparin1.3%Enoxaparin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
New England Journal of Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
James Crowe, MD
Vanderbilt University
Ingrid Mayer, MD
Vanderbilt University
Michael Debaun, MD
Vanderbilt University
Sam Chang, MD
Vanderbilt University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”